The advent of clustered regularly interspaced short palindromic repeat (CRISPR) genome
editing, coupled with advances in computing and imaging capabilities, has initiated a new …

In vivo gene editing therapies offer the potential to treat the root causes of many genetic
diseases. Realizing the promise of therapeutic in vivo gene editing requires the ability to …

Methods to deliver gene editing agents in vivo as ribonucleoproteins could offer safety
advantages over nucleic acid delivery approaches. We report the development and …

CRISPR-Cas9 gene editing has emerged as a powerful therapeutic technology, but the lack
of safe and efficient in vivo delivery systems, especially for tissue-specific vectors, limits its …

Extracellular vesicles (EVs) are gaining increasing attention for diagnostic and therapeutic
applications in various diseases. These natural nanoparticles benefit from favorable safety …

CRISPR-based drugs can theoretically manipulate any genetic target. In practice, however,
these drugs must enter the desired cell without eliciting an unwanted immune response, so …

Genome editing therapy for Duchenne muscular dystrophy (DMD) holds great promise,
however, one major obstacle is delivery of the CRISPR-Cas9/sgRNA system to skeletal …

CRISPR/Cas9 genome editing has gained rapidly increasing attentions in recent years,
however, the translation of this biotechnology into therapy has been hindered by efficient …

Extracellular vesicles (EVs) have emerged as a novel cell‐free strategy for the treatment of
many diseases including cancer. As a result of their natural properties to mediate cell‐to‐cell …

Rationale: A cell-specific delivery vehicle is required to achieve gene editing of the disease-
associated cells, so the hereditable genome editing reactions are confined within these cells …